Total Payments
$6,584
2024 Payments
$1,211
Companies
42
Transactions
468
Medicare Patients
398
Medicare Billing
$6,897
Payment Breakdown by Category
Food & Beverage$6,417 (97.5%)
Consulting$150.00 (2.3%)
Education$16.97 (0.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,417 | 465 | 97.5% |
| Consulting Fee | $150.00 | 1 | 2.3% |
| Education | $16.97 | 2 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $1,124 | 85 | $0 (2024) |
| Lilly USA, LLC | $766.97 | 58 | $0 (2024) |
| ABBVIE INC. | $645.39 | 41 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $412.69 | 25 | $0 (2024) |
| Amgen Inc. | $387.27 | 28 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $380.97 | 35 | $0 (2022) |
| PFIZER INC. | $366.81 | 36 | $0 (2023) |
| Novo Nordisk Inc | $293.69 | 26 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $258.13 | 12 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $200.98 | 12 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,211 | 73 | ABBVIE INC. ($277.81) |
| 2023 | $1,018 | 71 | AbbVie Inc. ($348.15) |
| 2022 | $791.03 | 53 | GlaxoSmithKline, LLC. ($196.39) |
| 2021 | $566.25 | 40 | GlaxoSmithKline, LLC. ($122.29) |
| 2020 | $288.89 | 20 | GlaxoSmithKline, LLC. ($82.65) |
| 2019 | $764.81 | 58 | GlaxoSmithKline, LLC. ($165.54) |
| 2018 | $842.98 | 65 | PFIZER INC. ($159.55) |
| 2017 | $1,102 | 88 | Boehringer Ingelheim Pharmaceuticals, Inc. ($189.44) |
All Payment Transactions
468 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/18/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.55 | General |
| Category: NEUROSCIENCE | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.77 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/27/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $21.12 | General |
| Category: PSYCHIATRY | ||||||
| 11/25/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $16.37 | General |
| Category: Gastroenterology | ||||||
| 11/22/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.50 | General |
| Category: NEUROSCIENCE | ||||||
| 11/21/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $11.69 | General |
| Category: Diabetes | ||||||
| 11/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.28 | General |
| Category: NEUROSCIENCE | ||||||
| 11/01/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $26.16 | General |
| Category: Diabetes | ||||||
| 10/28/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $7.94 | General |
| Category: Diabetes | ||||||
| 10/28/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $4.97 | General |
| Category: Diabetes | ||||||
| 10/23/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.84 | General |
| Category: NEUROSCIENCE | ||||||
| 10/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $13.58 | General |
| Category: Gastroenterology | ||||||
| 10/21/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $17.94 | General |
| Category: RESPIRATORY | ||||||
| 10/15/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $15.12 | General |
| Category: Diabetes | ||||||
| 10/14/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Food and Beverage | In-kind items and services | $29.31 | General |
| 10/10/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $27.98 | General |
| Category: NEUROSCIENCE | ||||||
| 10/07/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $17.62 | General |
| Category: RESPIRATORY | ||||||
| 09/30/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.04 | General |
| Category: NEUROSCIENCE | ||||||
| 09/17/2024 | Lilly USA, LLC | JARDIANCE (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $15.43 | General |
| Category: Diabetes | ||||||
| 09/12/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $14.62 | General |
| Category: Inflammation | ||||||
| 09/11/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $10.88 | General |
| Category: Diabetes | ||||||
| 09/02/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $19.11 | General |
| Category: RESPIRATORY | ||||||
| 08/27/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.25 | General |
| Category: Diabetes | ||||||
| 08/22/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.89 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 185 | 224 | $7,810 | $4,224 |
| 2022 | 4 | 83 | 119 | $3,230 | $1,581 |
| 2021 | 3 | 45 | 62 | $1,370 | $413.04 |
| 2020 | 5 | 85 | 107 | $2,565 | $678.61 |
Total Patients
398
Total Services
512
Medicare Billing
$6,897
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 17 | 17 | $1,275 | $1,224 | 96.0% |
| 87428 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | Office | 2023 | 23 | 30 | $1,800 | $945.48 | 52.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 22 | 22 | $550.00 | $539.00 | 98.0% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2023 | 12 | 13 | $520.00 | $450.06 | 86.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 32 | 46 | $1,840 | $333.20 | 18.1% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 18 | 27 | $275.00 | $257.04 | 93.5% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2023 | 12 | 13 | $520.00 | $210.86 | 40.6% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 20 | 20 | $600.00 | $130.16 | 21.7% |
| 82044 | Urine microalbumin (protein) analysis | Office | 2023 | 14 | 14 | $210.00 | $85.54 | 40.7% |
| 81003 | Automated urinalysis test | Office | 2023 | 15 | 22 | $220.00 | $48.40 | 22.0% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2022 | 27 | 34 | $1,360 | $1,182 | 86.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 25 | 38 | $1,520 | $331.79 | 21.8% |
| 81003 | Automated urinalysis test | Office | 2022 | 20 | 23 | $230.00 | $51.06 | 22.2% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2022 | 11 | 24 | $120.00 | $16.46 | 13.7% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 15 | 25 | $1,000 | $210.43 | 21.0% |
| 83036 | Hemoglobin a1c level | Office | 2021 | 13 | 16 | $160.00 | $155.36 | 97.1% |
| 81003 | Automated urinalysis test | Office | 2021 | 17 | 21 | $210.00 | $47.25 | 22.5% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 26 | 37 | $1,480 | $273.12 | 18.5% |
| 83036 | Hemoglobin a1c level | Office | 2020 | 15 | 20 | $200.00 | $191.35 | 95.7% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2020 | 15 | 16 | $480.00 | $87.60 | 18.3% |
| 82044 | Urine microalbumin (protein) analysis | Office | 2020 | 11 | 13 | $195.00 | $79.79 | 40.9% |
| 81003 | Automated urinalysis test | Office | 2020 | 18 | 21 | $210.00 | $46.75 | 22.3% |
About Dr. Eric Baumann, MD
Dr. Eric Baumann, MD is a Family Medicine healthcare provider based in Owenton, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1538194162.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Baumann, MD has received a total of $6,584 in payments from pharmaceutical and medical device companies, with $1,211 received in 2024. These payments were reported across 468 transactions from 42 companies. The most common payment nature is "Food and Beverage" ($6,417).
As a Medicare-enrolled provider, Baumann has provided services to 398 Medicare beneficiaries, totaling 512 services with total Medicare billing of $6,897. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Owenton, KY
- Active Since 07/12/2006
- Last Updated 12/05/2018
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1538194162
Products in Payments
- TRELEGY ELLIPTA (Drug) $946.33
- VRAYLAR (Drug) $606.18
- JARDIANCE (Drug) $479.59
- MOUNJARO (Drug) $390.05
- XARELTO (Drug) $343.45
- FARXIGA (Drug) $234.48
- ENTRESTO (Drug) $200.98
- XIFAXAN (Drug) $187.83
- Aimovig (Biological) $168.23
- TRULICITY (Drug) $156.98
- Vascepa (Drug) $152.57
- GARDASIL (Biological) $150.00
- Victoza (Drug) $143.17
- CHANTIX (Drug) $119.47
- Otezla (Drug) $117.83
- Myrbetriq (Drug) $116.77
- ANORO (Drug) $103.88
- LYRICA (Drug) $82.10
- ELIQUIS (Drug) $74.93
- LINZESS (Drug) $66.35
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.